category guide

How to Choose Sleep Study Systems

April 30, 2026· 9 min read· AI-generated

How to Choose Sleep Study Systems

A procurement guide for hospital sleep labs, independent sleep centers, and specialty practices navigating polysomnography platform decisions.

What this is and who buys it

A polysomnography (PSG) system is a multi-channel physiological recorder that simultaneously captures EEG, EOG, chin and leg EMG, ECG, nasal/oral airflow, respiratory effort, pulse oximetry, body position, and snore audio — typically across 22 or more electrode and sensor attachment points per patient. The resulting overnight recording is the clinical foundation for diagnosing obstructive and central sleep apnea, parasomnias, narcolepsy, periodic limb movement disorder, and nocturnal seizures. In-lab systems are permanently installed in shielded recording rooms and include synchronized digital video; home sleep apnea testing (HSAT) devices are ambulatory variants that sacrifice EEG and video for portability.

The buyers are varied: AASM-accredited hospital sleep laboratories replacing end-of-life Embla N7000 or Philips Alice 5/6 platforms; neurology departments adding PSG capacity to existing neurodiagnostic infrastructure; independent sleep centers under reaccreditation pressure; and pulmonology or ENT practices building HSAT-first diagnostic workflows. Pediatric hospitals form a distinct sub-segment with age-specific montage and respiratory sensor requirements that not all platforms support out of the box.

Procurement cycles in this category are rarely elective. They tend to be triggered by one of three events: an AASM accreditation cycle demanding updated standards compliance, announced end-of-software-support on a legacy platform, or volume growth that exhausts existing bed capacity. Understanding which driver applies to your lab shapes how aggressively you negotiate on price versus how quickly you need a system operational.

Key decision factors

Channel count and amplifier headroom matters more than vendors typically acknowledge in demo environments. A standard PSG requires at least 22 wire attachments across a minimum of 12 channels, but specifying ≥24 inputs provides crucial flexibility: if an EEG electrode fails mid-study, a tech with no spare channels has no recovery path and may be forced to terminate or restart the recording [S6]. Labs expecting seizure rule-out protocols should specify enough inputs for a full 10-20 EEG montage simultaneously with all PSG channels — a capability common in research-grade platforms but absent in some entry-level clinical systems.

Study type coverage determines whether you need one platform or two separate procurement decisions. The spectrum runs from Type I (attended in-lab PSG) through Level 2 (unattended full PSG with a minimum of 7 channels including EEG, EOG, chin EMG, and Level 3 signals) to Type 3 HSAT (cardiorespiratory only, no EEG). Labs that want to offer all three without running parallel scoring workflows should confirm that the software stack supports all study types natively — not through bolt-on modules with different scoring interfaces.

AASM Scoring Manual compliance is a non-negotiable baseline for accredited operations. The current AASM Scoring Manual specifies both 'RECOMMENDED' and 'ACCEPTABLE' montages, and facilities must use one of these [S4]. Practically, this means asking vendors to show you factory-configured montages mapped to the current manual version before purchase — not a promise that montages "can be configured" post-installation.

Signal integrity is defined operationally by impedance thresholds: EEG, ECG, and EOG channels must stay below 5 kΩ; EMG channels below 10 kΩ [S6]. Systems that display impedance continuously at the headbox — rather than requiring a separate pre-study check — allow technologists to intervene immediately when electrode contact degrades, rather than discovering bad data at morning review.

AI auto-scoring software is now a real labor multiplier rather than a novelty. Platforms such as EnsoSleep (FDA cleared under K210034 [S3]) and RemLogic (K162140 [S2]) can process a full-night recording in minutes. However, FDA clearance alone does not guarantee clinical accuracy on your patient population; validated percent-agreement and kappa statistics against expert manual scoring should be requested in writing, and the regulatory requirement that all auto-scored studies be verified and edited by credentialed staff (RPSGT, CPSGT, or qualified RT) remains firm regardless of algorithm performance [S4].

Wireless versus tethered headboxes present a genuine tradeoff. Wireless setups reduce patient cable artifact and setup time, which matters in high-volume labs running back-to-back studies. The risk is RF dropout — if the headbox lacks onboard memory and automatic re-sync when the patient returns to coverage range, you face data loss that can invalidate a study. Any wireless headbox specification should include confirmation of internal memory fallback as a hard requirement, not an optional add-on.

Data export and interoperability may seem like an IT concern, but it is a 10-year financial decision. PSG platforms with closed proprietary file formats lock your facility into that vendor's scoring software for the life of the hardware — typically 7-10 years for amplifiers. Requiring open EDF/EDF+ export and documented HL7/FHIR EHR integration pathways (Epic, Cerner, Meditech) at RFP stage is the only reliable protection against vendor lock-in.

What it costs

PSG system pricing varies dramatically by channel count, whether the study type is in-lab or ambulatory, and whether the unit is new or refurbished. The ranges below reflect broadly available market data; premium-tier pricing is not publicly published and must be confirmed by direct RFQ [S12].

Entry: $8,000–$20,000 per bed — Refurbished limited-channel HSAT/Type 3 systems or legacy refurbished in-lab units. Secondary market platforms (DOTmed, Bimedis) carry units in this range, but software currency is the critical caveat.
Mid-range: $20,000–$45,000 per bed — New 24–32 channel in-lab PSG with auto-scoring software, synchronized video, and a one-year warranty. This band covers most AASM-accredited clinical lab purchases.
Premium: $50,000–$90,000+ per bed — High-density research or combined PSG/EEG systems with 55–70 channels. Manufacturers do not publish list prices at this tier; budget figures are estimates requiring formal quotation.

Common use cases

Sleep study systems serve a wider range of clinical and research contexts than the basic OSA diagnosis framing suggests. Labs should match platform capability to their realistic patient mix rather than procuring to the highest-complexity use case they might eventually encounter.

AASM-accredited in-lab sleep centers conducting comprehensive Type I PSG, MSLT, MWT, and PAP titration studies as the core clinical workflow.
Hospital neurodiagnostic departments using combined PSG/EEG configurations to differentiate parasomnias from nocturnal seizures — a differentiation that requires simultaneous full 10-20 EEG acquisition [S11].
Pediatric sleep labs requiring age-appropriate respiratory sensors, pediatric body position monitors, and scoring montages distinct from adult standards.
Pulmonology and ENT practices deploying HSAT-first pathways with Type 3 devices for straightforward OSA cases and reserving in-lab escalation for complex or comorbid presentations.

Regulatory and compliance

PSG hardware and automatic-scoring software are regulated by the FDA primarily under 21 CFR 882.1400, product code OLZ, as Class II devices cleared via 510(k) premarket notification. HSAT devices follow the same Class II pathway, with clearance contingent on demonstrating substantial equivalence to a predicate device. Apnea monitors fall under 21 CFR 868.2375/868.2377. Required engineering standards include IEC 60601-1 (general electrical safety for medical electrical equipment), IEC 60601-1-2 (electromagnetic compatibility), and ISO 10993 for biocompatibility of patient-contact electrodes. Request the 510(k) clearance letter and confirm the indications-for-use statement covers your intended patient population, including pediatric age bands if applicable.

For AASM-accredited operations, facilities must maintain a written equipment monitoring plan with monthly visual inspection by staff, adherence to manufacturer maintenance recommendations, and annual electrical safety testing by a certified electrician or biomedical engineer — documented in an equipment maintenance log [S4]. HIPAA governs all PSG records, video files, and cloud-stored EDFs; storage must be secure and retrievable, with retention periods complying with applicable state statutes — commonly a seven-year minimum for adults and longer for pediatric patients [S5].

Service, training, and total cost of ownership

Vendor-led installation for a multi-bed lab typically runs two to five days and covers amplifier and headbox configuration, network and PACS integration, AASM-compliant montage setup, and video/audio synchronization calibration. Underestimating this phase is common: if EHR integration is not fully tested before go-live, scoring workflows stall and studies accumulate in a manual backlog.

Training for new platforms typically requires 16–40 hours per technologist for RPSGT-led instruction, and that estimate assumes staff are already familiar with PSG fundamentals. For labs migrating from a legacy platform with different electrode nomenclature or impedance check workflows, budget additional time. Annual service contracts typically run 8–15% of the system purchase price and should explicitly cover amplifier swap-out, software updates aligned to AASM Scoring Manual revisions, and consumable replacement (electrodes, nasal cannulas, effort belts). Hardware amplifiers and headboxes realistically last 7–10 years; software platforms are typically supported 5–7 years before a forced upgrade cycle. Parts availability for legacy systems is narrowing — OEM support pipelines for Philips Respironics Alice and older Embla units are active but not indefinite.

Red flags to watch for

A vendor quoting a per-bed headbox price without disclosing per-bed software licensing fees, annual scoring-engine subscriptions, or cloud storage fees is obscuring the true 5-year cost of ownership — request an itemized 5-year TCO sheet before any formal comparison. Platforms that cannot export native EDF/EDF+ without proprietary wrappers should be treated as a long-term lock-in risk, not a minor inconvenience. AI auto-scoring claims deserve particular scrutiny: FDA clearance of an algorithm does not equate to validated accuracy on your specific patient mix, and published agreement statistics (percent agreement and Cohen's kappa) versus expert manual scoring for staging, apneas, hypopneas, and arousals should be available in writing, not marketing language [S3]. Finally, amplifiers sold with only the minimum required channel count leave no recovery margin — if a single EEG channel fails mid-study and no spare inputs exist, the recording may be unscoreable [S6].

Questions to ask vendors

What is the 510(k) K-number and product code, and does the cleared indications-for-use statement explicitly cover your intended patient population (adult, pediatric ≥13, pediatric <13, ICU)?
How many simultaneous referential and bipolar inputs does the amplifier support, what is the per-channel sampling rate, and what is the ADC bit depth (16-bit versus 24-bit)?
Does the system export native EDF/EDF+ without proprietary wrappers, and what is the documented HL7/FHIR integration pathway for your specific EHR platform?
What are the published auto-scoring agreement statistics (percent agreement, Cohen's kappa) against expert manual scoring for sleep staging, apneas, hypopneas, and arousals — and on what patient population were those metrics derived?
What is the itemized 5-year total cost of ownership per bed, including software licenses, scoring-engine subscription fees, cloud storage, consumables, and annual service contract?
What is your guaranteed parts and service support window in years, what is the mean repair turnaround time for amplifier failure, and do you provide loaner hardware during repair?

Alternatives

The decision between new and refurbished, and between purchase and lease, depends heavily on your accreditation timeline and biomed support capacity. Refurbished Embla N7000, Alice 5/6, and Compumedics Safiro units are readily available on secondary markets at significantly lower upfront cost [S12], but the critical variable is whether the installed scoring software version is upgrade-eligible to current AASM Scoring Manual compliance — a point that must be confirmed in writing before any refurbished purchase.

Refurbished in-lab PSG: Lower acquisition cost ($8,000–$20,000/bed), but verify OEM recertification, current calibration certificate, and software upgrade eligibility before committing.
36–60 month operating leases: Typically $400–$1,200/month per bed; preserve capital and bundle service, but total cost runs 15–25% above outright purchase over the lease term. Most practical when accreditation-driven refresh cycles shorten effective hardware life.
Capital purchase with service contract: Lowest 7–10 year TCO if your biomed team handles Level 1 troubleshooting and you negotiate parts availability commitments upfront.
HSAT-first model: For OSA-dominant referral mixes, deploying Type 3 HSAT units at $1,500–$4,000 per device can reduce in-lab capital requirements by 60–70%, reserving full PSG capacity for complex or comorbid cases.
Cloud-based AI scoring services: Platforms like EnsoSleep and Cerebra can meaningfully reduce scorer labor in high-volume labs, but credentialed staff verification of every scored study remains a regulatory requirement — these services augment registered techs, they do not replace them [S4].

Sources

Browse vendors in

Sleep Study Systems

MedSource publishes neutral guidance. We do not accept payment from vendors to influence the content of articles. AI-generated articles are reviewed for factual accuracy but cited sources should be the primary reference for procurement decisions.